Intraperitoneal immunotherapy of human ovarian carcinoma with recombinant interferon: A phase I toxicity/immunopharmacology study

Berek, J. S.; Nf, Hacker; Lichtenstein, Alan; Jung, Tyler; Knox, Reba M.; Greene, Teri; Bonnem, Eric M.; Lagasse, Leo D.; Zighelboim, Jacob

doi:10.1016/0090-8258(85)90180-5

Cited by 4 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This activity is normally related to drug concentra tion and time of exposure [18,19], Our study particularly confirms the efficacy of intraperitoneal IFN in patients with minimally pretreated residual ovarian cancer: the median survival of our pa tients has reached 25.5 months ( fig. 1) versus 6 or 7 months in the patients of Bruckner et al [20] who were treated without IFN therapy, confirming the efficacy of intraperitoneal IFN in minimal residual ovarian cancer [3]: all cases (10/10) with microscopic residues became CR; while of the 7 cases with macroscopic residues only 3 be came PR. We did not find any relation between IFN dose administered and therapy result.…”

Section: Discussionmentioning

confidence: 50%

“…From these data we expected that the cytology would have become ne gative after a-IFN therapy, but we cannot confirm this. The data of Berek et al [3] show 60% CR of the 5 tested patients with positive cytology.…”

Section: Discussionmentioning

confidence: 99%

“…The ad ministration is tolerated by tissues without severe inflam matory or painful reactions [1,3]. Clinical experiences [3,4,10] confirm that intra peritoneally administered IFN is particularly effective on minimal tumor residues. Dosage and administration schedule adopted by various authors are summarized in table 1.…”

Section: Introductionmentioning

confidence: 89%

“…It seems logical to us as well as to others [3,5,24,25] to extend the intraperitoneal treatment to all cases with mi croscopic residua and probably to use it during the con solidation phase after pathological CR from ovarian can cer.…”

Section: Discussionmentioning

confidence: 99%

“…Intraperitoneal treatment with human recombinant a-IFN has been reported to be effective in patients with ova rian cancer [3,4], Diluting the intraperitoneally administered drugs in a large fluid volume has given pharmacologic and biological advantage [5,6]; it not only provided a more even distribu tion, but also a longer dwelling of the drug is obtained.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Experience with Intraperitoneal Alpha-2a Interferon

Nicoletto

Fiorentino

Vinante³

et al. 1992

Oncology

View full text Add to dashboard Cite

Eighteen patients affected with epithelial ovarian cancer have been treated by intraperitoneal α_2a-Interferon. The usual single dosage was 54 x 10⁶ U at weekly intervals for four times (eight times in responders): 10 h-istologically confirmed complete remissions and 3 partial remissions have been obtained; the toxicity was represented by fever in the majority of the cases, by abdominal discomfort in some cases, and by a mild transitory neurological complication in 1 case. Seventeen of 18 patients were pretreated, and 11 of 18 had only cytologic and/or microscopic disease. α_2a-Interferon has proven to be very effective and moderately toxic in microscopic peritoneal disease of ovarian epithelial cancer previously treated with extensive surgery and intravenous cytotoxic chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 50%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Experience with Intraperitoneal Alpha-2a Interferon

Nicoletto

Fiorentino

Vinante³

et al. 1992

Oncology

View full text Add to dashboard Cite

show abstract

Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavity

Markman

1986

Cancer Treatment Reviews

View full text Add to dashboard Cite

Use of in vitro dose response effects to select antineoplastics for high-dose or regional administration regimens.

Hoff¹,

Clark²,

Weiss³

et al. 1986

JCO

View full text Add to dashboard Cite

Several preclinical and clinical studies have documented that dose or dose intensity of chemotherapeutic agents are important factors for response of patients' tumors. This finding has prompted empiric trials of certain chemotherapeutic agents in high-dose or regional administration treatment regimens. The present study was performed to identify agents that would be particularly good candidates for high-dose or regional administration regimens against particular types of tumors. Using a human tumor cloning technique, we constructed dose in vitro response lines for ten different chemotherapeutic agents against seven different histologic types of malignancies. Slopes of the lines indicated the agents with the greatest increases of in vitro response per increment in dose of the agent. Tumors against which the agents gave the steepest dose response lines included lymphoma, head and neck cancer, ovarian cancer, and small-cell lung cancer, while the dose response lines for non-small-cell lung cancer, breast cancer, and colon cancer were quite flat. Suggestions for clinical trials based on these findings include the use of high-dose melphalan for patients with lymphoma, head and neck, and ovarian cancer; the use of mitoxantrone in high-dose regimens for patients with breast cancer; high-dose cisplatin regimens for patients with small-cell lung cancer; high-dose bleomycin regimens for patients with non-small-cell lung and head and neck cancer; and regional perfusion of liver metastases from colorectal cancer with cisplatin. Prospective testing of high-dose or regional administration regimens suggested by this new model should indicate its use for prediction of the best agent to use in high-dose regimens against a particular tumor type.

show abstract

Intraperitoneal immunotherapy of human ovarian carcinoma with recombinant interferon: A phase I toxicity/immunopharmacology study

Cited by 4 publications

References 0 publications

Experience with Intraperitoneal Alpha-2a Interferon

Experience with Intraperitoneal Alpha-2a Interferon

Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavity

Use of in vitro dose response effects to select antineoplastics for high-dose or regional administration regimens.

Contact Info

Product

Resources

About